STOCK TITAN

IDEAYA Biosciences, Inc. - IDYA STOCK NEWS

Welcome to our dedicated page for IDEAYA Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on IDEAYA Biosciences stock.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is an innovative biotechnology firm concentrated on oncology. Established in 2015 and headquartered in South San Francisco and La Jolla, California, the company is dedicated to the discovery and development of precision medicine therapies for genetically defined patient groups. Their focus areas include synthetic lethality and immuno-oncology, targeting DNA damage repair mechanisms and the tumor microenvironment, respectively.

IDEAYA's pioneering approach leverages molecular diagnostics to identify and develop targeted therapeutics. The company's leading product candidate, IDE196, is a potent inhibitor of protein kinase C (PKC), aimed at treating cancers with GNAQ or GNA11 mutations. In addition, IDEAYA is advancing several clinical programs, such as the darovasertib program, which is currently in Phase 2 trials for uveal melanoma (UM) and has shown promising results in tumor shrinkage and eye preservation.

In synthetic lethality, IDEAYA's IDE397 targets methionine adenosyltransferase 2 alpha (MAT2A) in solid tumors with MTAP deletion, a condition prevalent in 15% of solid tumors. The IDE397 program includes both monotherapy and combination trials with other investigational drugs.

Financially, IDEAYA is robust with cash reserves exceeding $941.4 million as of Q1 2024, ensuring operational funding through 2028. Key investors include 5AM Ventures, Canaan Partners, and Celgene. The company has formed strategic collaborations with major pharmaceutical players like Pfizer, Amgen, Gilead Sciences, GSK, and Merck to amplify its research and clinical capabilities.

IDEAYA's scientific advisory board is composed of esteemed researchers, including a Nobel laureate and members of the National Academy of Sciences, underscoring the company's commitment to groundbreaking research.

Recent developments are promising: IDEAYA reported favorable Phase 2 trial results for IDE196 in UM, with significant tumor reduction and eye preservation rates. Additionally, a collaboration with Merck for the IDE161 program aims to tackle endometrial cancer using advanced immunotherapy combinations.

For more detailed updates and financial information, visit IDEAYA's Investor Relations page.

Rhea-AI Summary

IDEAYA Biosciences (IDYA) has collaborated with Pfizer (PFE) to enhance clinical trials evaluating the combination of darovasertib and crizotinib in patients with metastatic uveal melanoma (MUM) and cMET-driven tumors. The Phase 2 trial could enable registration, with promising preliminary data showing robust activity. IDEAYA plans to provide an update on clinical data in mid-2022 and will seek FDA guidance for trial design. This partnership aims to elevate treatment standards for patients with high unmet needs and potentially expand to other cancer types.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
-
Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) is set to host an Investor Webcast on March 15, 2022, to discuss interim clinical data for IDE397, a potential MAT2A inhibitor in a Phase 1 clinical trial. This trial focuses on patients with tumors featuring MTAP deletions. The call will cover dose escalation data, adverse events, and pharmacokinetic information, alongside the financial results for Q4 and the full year 2021. The company emphasizes its commitment to precision oncology through targeted therapeutic development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
conferences clinical trial
-
Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, announced its participation in several investor conferences in March 2022. Key events include the Guggenheim 3rd Annual Healthy Altitudes CEO Summit on March 10, the Oppenheimer Targeted Oncology Panel on March 14, and the 34th Annual Roth Conference on the same day. CEO Yujiro Hata and CFO Paul Stone will represent the company. Live audio webcasts will be available on IDEAYA's website, with replays accessible for 30 days following the events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
conferences
Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) announced participation in Guggenheim Oncology Day on February 9, 2022, at 3:30 PM ET. CEO Yujiro Hata will engage in a fireside chat hosted by Charles Zhu, Ph.D. A live audio webcast will be accessible through IDEAYA’s website, with a replay available for 30 days post-event. IDEAYA focuses on precision medicine for oncology, utilizing synthetic lethality to develop targeted therapeutics based on molecular diagnostics. For more details, visit the Investor Calendar.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
conferences
-
Rhea-AI Summary

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced the initiation of IND-enabling studies for IDE161, a potential first-in-class PARG inhibitor. The company has exercised its option for an exclusive worldwide license from Cancer Research UK and the University of Manchester. IDE161 targets tumors with homologous recombination deficiencies, including those with BRCA1 and BRCA2 mutations. IDEAYA plans to submit an IND application for IDE161 in Q4 2022, following successful preclinical studies. The company holds comprehensive rights to IDE161 under its licensing agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
none
-
Rhea-AI Summary

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced key corporate updates ahead of the J.P. Morgan 40th Annual Healthcare Conference on January 11, 2022. The company reported a robust balance sheet with approximately $386 million in cash and equivalents, expected to fund operations into 2025. They completed enrollment in the Phase 1 trial for IDE397, targeting FDA amendment in Q1 2022. Additionally, IDEAYA aims to submit IND for a PARG inhibitor by Q4 2022 and expand indications for darovasertib. GSK milestone payments of $70 million could be triggered through upcoming developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.78%
Tags
none
Rhea-AI Summary

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced on January 5, 2022, the acquisition of its INQUIRE™ Chemical Library, a curated collection of over 200,000 compounds aimed at enhancing the company's synthetic lethality drug discovery platform. This acquisition is expected to improve IDEAYA's hit discovery capabilities across challenging targets such as helicases and endonucleases. The company aims to leverage this proprietary library alongside its existing expertise in drug discovery, aiming for advancements in targeted therapeutics and innovative drug candidates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.37%
Tags
-
Rhea-AI Summary

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) has appointed Frank McCormick, Ph.D., FRS, as the Chair of its Scientific Advisory Board. Dr. McCormick is a renowned expert in cancer biology and has a significant background in drug discovery. IDEAYA is known for its pioneering synthetic lethality approach in oncology, developing targeted therapeutics such as darovasertib and IDE397. Dr. McCormick's leadership is expected to enhance IDEAYA's clinical and preclinical pipeline, driving advancements in precision medicine for cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.12%
Tags
management
-
Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) will participate in several investor conferences throughout January 2022, showcasing its focus on precision medicine in oncology.

The events include the LifeSci Advisors Corporate Access Event on January 6, the J.P. Morgan 40th Annual Healthcare Conference on January 11, and the B. Riley Securities' 2022 Oncology Conference on January 27. CEO Yujiro Hata will present at all conferences, emphasizing IDEAYA's commitment to synthetic lethality and patient-targeted therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
conferences
Rhea-AI Summary

IDEAYA Biosciences (Nasdaq:IDYA) announced a clinical update on its Phase 1/2 trial combining darovasertib and crizotinib for metastatic uveal melanoma (MUM) patients. With 22 heavily pre-treated patients enrolled, the interim results show a remarkable 100% Disease Control Rate and a 31% Overall Response Rate. The data suggests potential as a new treatment benchmark in this area with high unmet medical need. IDEAYA is also exploring the combination in other tumor types and expects further clinical data in 2022, aimed at regulatory feedback for potential registration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.59%
Tags

FAQ

What is the current stock price of IDEAYA Biosciences (IDYA)?

The current stock price of IDEAYA Biosciences (IDYA) is $25.61 as of December 20, 2024.

What is the market cap of IDEAYA Biosciences (IDYA)?

The market cap of IDEAYA Biosciences (IDYA) is approximately 2.1B.

What is IDEAYA Biosciences, Inc.?

IDEAYA Biosciences, Inc. is a biotechnology company focused on the discovery and development of precision medicine therapies for oncology.

What is the primary focus of IDEAYA's research?

IDEAYA focuses on synthetic lethality and immuno-oncology, targeting DNA damage repair and the tumor microenvironment for genetically defined patient populations.

What is IDEAYA's product pipeline?

IDEAYA's pipeline includes IDE196 for cancers with GNAQ or GNA11 mutations, IDE397 for MTAP-deleted tumors, and IDE161 targeting tumors with homologous recombination deficiency (HRD).

Who are IDEAYA's key investors?

Key investors include 5AM Ventures, Canaan Partners, Celgene, WuXi Healthcare Ventures, Novartis Institute of Biomedical Research, and Alexandria Real Estate.

Where is IDEAYA Biosciences located?

IDEAYA has offices in South San Francisco and La Jolla, California.

What recent collaborations has IDEAYA announced?

IDEAYA has announced collaborations with Pfizer, Amgen, Gilead Sciences, GSK, and Merck to strengthen its research and clinical capabilities.

What significant achievements has IDEAYA made recently?

Significant achievements include promising Phase 2 trial results for IDE196 in uveal melanoma and the advancement of IDE397 and IDE161 in clinical trials.

What is IDEAYA's financial outlook?

As of Q1 2024, IDEAYA had cash and marketable securities totaling $941.4 million, projected to fund operations through 2028.

Who comprises IDEAYA's scientific advisory board?

IDEAYA's scientific advisory board includes a Nobel laureate and members of the National Academy of Sciences, underscoring their commitment to top-tier research.

How can I stay updated on IDEAYA Biosciences?

You can stay updated on IDEAYA Biosciences by visiting their Investor Relations page at https://ir.ideayabio.com/.

IDEAYA Biosciences, Inc.

Nasdaq:IDYA

IDYA Rankings

IDYA Stock Data

2.14B
85.54M
1.04%
111.21%
11.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO